Anebulo Pharmaceuticals Investor Relations Material

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase 2 clinical trial to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.